Driver Fusions and Their Implications in the Development and Treatment of Human Cancers

Abstract

Gene fusions represent an important class of somatic alterations in cancer. We systematically investigated fusions in 9,624 tumors across 33 cancer types using multiple fusion calling tools. We identified a total of 25,664 fusions, with a 63% validation rate. Integration of gene expression, copy number, and fusion annotation data revealed that fusions involving oncogenes tend to exhibit increased expression, whereas fusions involving tumor suppressors have the opposite effect. For fusions involving kinases, we found 1,275 with an intact kinase domain, the proportion of which varied significantly across cancer types. Our study suggests that fusions drive the development of 16.5% of cancer cases and function as the sole driver in more than 1% of them. Finally, we identified druggable fusions involving genes such as TMPRSS2, RET, FGFR3, ALK, and ESR1 in 6.0% of cases, and we predicted immunogenic peptides, suggesting that fusions may provide leads for targeted drug and immune therapy.

References 46

1. 1.

   Andreatta M, Nielsen M. Gapped sequence alignment using artificial neural networks: application to the MHC class I system. Bioinformatics. 2016;32:511-517.

   Not in our library10.1093/bioinformatics/btv639

2. 2.

   Babiceanu M, Qin F, Xie Z, Jia Y, Lopez K, Janus N, Facemire L, Kumar S, Pang Y, Qi Y, et al. Recurrent chimeric fusion RNAs in non-cancer tissues and cells. Nucleic Acids Res. 2016;44:2859-2872.

   Not in our library10.1093/nar/gkw032

3. 3.

   Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, Colaprico A, Wendl MC, Kim J, Reardon B, et al. Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell. 2018;173.

   Not in our library10.1016/j.cell.2018.02.060

4. 4.

   Bass AJ, Lawrence MS, Brace LE, Ramos AH, Drier Y, Cibulskis K, Sougnez C, Voet D, Saksena G, Sivachenko A, et al. Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nat Genet. 2011;43:964-968.

   Not in our library10.1038/ng.936

5. 5.

   Benelli M, Pescucci C, Marseglia G, Severgnini M, Torricelli F, Magi A. Discovering chimeric transcripts in paired-end RNA-seq data by using EricScript. Bioinformatics. 2012;28:3232-3239.

   Not in our library10.1093/bioinformatics/bts617

6. 6.

   Bobisse S, Foukas PG, Coukos G, Harari A. Neoantigen-based cancer immunotherapy. Ann Transl Med. 2016;4:262.

   Not in our library10.21037/atm.2016.06.17

7. 7.

   Boyle AP, Davis S, Shulha HP, Meltzer P, Margulies EH, Weng Z, Furey TS, Crawford GE. High-resolution mapping and characterization of open chromatin across the genome. Cell. 2008;132:311-322.

   Not in our library10.1016/j.cell.2007.12.014

8. 8.

   Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61-70.

   Not in our library10.1038/nature11412

9. 9.

   Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013a;497:67-73.

   Not in our library10.1038/nature12113

10. 10.

    Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, Robertson A, Hoadley K, Triche TJ, Laird PW, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013b;368:2059-2074.

    Not in our library10.1056/nejmoa1301689

11. 11.

    Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507:315-322.

    Not in our library10.1038/nature12965

12. 12.
    Integrated genomic and molecular characterization of cervical cancer · 2017

    No notice
13. 13.

    Cao S, Wendl MC, Wyczalkowski MA, Wylie K, Ye K, Jayasinghe R, Xie M, Wu S, Niu B, Grubb R, et al. Divergent viral presentation among human tumors and adjacent normal tissues. Sci Rep. 2016;6:28294.

    Not in our library10.1038/srep28294

14. 14.
    Genomic analysis of oesophageal squamous-cell carcinoma identifies alcohol drinking-related mutation signature and genomic alterations · 2017

    No notice
15. 15.

    Cilloni D, Saglio G. Molecular pathways: BCR-ABL. Clin Cancer Res. 2012;18:930-937.

    Not in our library10.1158/1078-0432.ccr-10-1613

16. 16.

    The Genotype-Tissue Expression (GTEx) project. Nat Genet. 2013;45:580-585.

    Not in our library10.1038/ng.2653

17. 17.

    Dinh TA, Vitucci EC, Wauthier E, Graham RP, Pitman WA, Oikawa T, Chen M, Silva GO, Greene KG, Torbenson MS, et al. Comprehensive analysis of The Cancer Genome Atlas reveals a unique gene and non-coding RNA signature of fibrolamellar carcinoma. Sci Rep. 2017;7:44653.

    Not in our library10.1038/srep44653

18. 18.

    Ellrott K, Bailey MH, Saksena G, Covington KR, Kandoth C, Stewart C, Hess J, Ma S, McLellan M, Sofia HJ, et al. Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. Cell Syst. 2018;6.

    Not in our library10.1016/j.cels.2018.03.002

19. 19.

    Giacomini CP, Sun S, Varma S, Shain AH, Giacomini MM, Balagtas J, Sweeney RT, Lai E, Del Vecchio CA, Forster AD, et al. Break-point analysis of transcriptional and genomic profiles uncovers novel gene fusions spanning multiple human cancer types. PLoS Genet. 2013;9:e1003464.

    Not in our library10.1371/journal.pgen.1003464

20. 20.

    Haferlach C, Dicker F, Kohlmann A, Schindela S, Weiss T, Kern W, Schnittger S, Haferlach T. AML with CBFB-MYH11 rearrangement demonstrate RAS pathway alterations in 92% of all cases including a high frequency of NF1 deletions. Leukemia. 2010;24:1065-1069.

    Not in our library10.1038/leu.2010.22

21. 21.

    Hantschel O. Structure, regulation, signaling, and targeting of abl kinases in cancer. Genes Cancer. 2012;3:436-446.

    Not in our library10.1177/1947601912458584

22. 22.

    Hass B, Dobin A, Stransky N, Li B, Yang X, Tickle T, Bankapur A, Ganote C, Doak T, Pochet N, et al. STAR-Fusion: Fast and Accurate Fusion Transcript Detection from RNA-Seq. bioRxiv. 2017.

    Not in our library

23. 23.

    Hornbeck PV, Zhang B, Murray B, Kornhauser JM, Latham V, Skrzypek E. PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Nucleic Acids Res. 2015;43:D512-D520.

    Not in our library10.1093/nar/gku1267

24. 24.

    Hu X, Wang Q, Tang M, Barthel F, Amin S, Yoshihara K, Lang FM, Martinez-Ledesma E, Lee SH, Zheng S, et al. TumorFusions: an integrative resource for cancer-associated transcript fusions. Nucleic Acids Res. 2018;46:D1144-D1149.

    Not in our library10.1093/nar/gkx1018

25. 25.

    Jones DT, Kocialkowski S, Liu L, Pearson DM, Backlund LM, Ichimura K, Collins VP. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 2008;68:8673-8677.

    Not in our library10.1158/0008-5472.can-08-2097

26. 26.

    Kanchi KL, Johnson KJ, Lu C, McLellan MD, Leiserson MD, Wendl MC, Zhang Q, Koboldt DC, Xie M, Kandoth C, et al. Integrated analysis of germline and somatic variants in ovarian cancer. Nat Commun. 2014;5:3156.

    Not in our library10.1038/ncomms4156

27. 27.

    Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502:333-339.

    Not in our library10.1038/nature12634

28. 28.
    Landscape of gene fusions in epithelial cancers: seq and ye shall find · 2015

    No notice
29. 29.

    Lasorella A, Sanson M, Iavarone A. FGFR-TACC gene fusions in human glioma. Neuro-oncol. 2017;19:475-483.

    Not in our library10.1093/neuonc/now240

30. 30.

    Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, Meyerson M, Gabriel SB, Lander ES, Getz G. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014;505:495-501.

    Not in our library10.1038/nature12912

31. 31.

    Lee M, Lee K, Yu N, Jang I, Choi I, Kim P, Jang YE, Kim B, Kim S, Lee B, et al. ChimerDB 3.0: an enhanced database for fusion genes from cancer transcriptome and literature data mining. Nucleic Acids Res. 2017;45:D784-D789.

    Not in our library10.1093/nar/gkw1083

32. 32.

    Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, He X, Liu S, Hoog J, Lu C, et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep. 2013;4:1116-1130.

    Not in our library10.1016/j.celrep.2013.08.022

33. 33.

    Lu H, Villafane N, Dogruluk T, Grzeskowiak CL, Kong K, Tsang YH, Zagorodna O, Pantazi A, Yang L, Neill NJ, et al. Engineering and functional characterization of fusion genes identifies novel oncogenic drivers of cancer. Cancer Res. 2017;77:3502-3512.

    Not in our library10.1158/0008-5472.can-16-2745

34. 34.

    Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM. Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol. 2017;14:100-113.

    Not in our library10.1038/nrclinonc.2016.122

35. 35.

    Mignone F, Gissi C, Liuni S, Pesole G. Untranslated regions of mRNAs. Genome Biol. 2002;3:reviews0004.1-reviews0004.10.

    Not in our library10.1186/gb-2002-3-3-reviews0004

36. 36.

    Moniz S, Jordan P. Emerging roles for WNK kinases in cancer. Cell Mol Life Sci. 2010;67:1265-1276.

    Not in our library10.1007/s00018-010-0261-6

37. 37.

    Murphy C, Elemento O. AGFusion: annotate and visualize gene fusions. bioRxiv. 2016.

    Not in our library

38. 38.

    Palanisamy N, Ateeq B, Kalyana-Sundaram S, Pflueger D, Ramnarayanan K, Shankar S, Han B, Cao Q, Cao X, Suleman K, et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med. 2010;16:793-798.

    Not in our library10.1038/nm.2166

39. 39.

    Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 2005;5:172-183.

    Not in our library10.1038/nrc1567

40. 40.

    Sinclair A, Latif AL, Holyoake TL. Targeting survival pathways in chronic myeloid leukaemia stem cells. Br J Pharmacol. 2013;169:1693-1707.

    Not in our library10.1111/bph.12183

Cited by papers we hold 11

• Neoantigens: promising targets for cancer therapy · 2023
  No notice
• Accurate and efficient detection of gene fusions from RNA sequencing data · 2021
  No notice
• Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study · 2020
  Not checked
• MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas · 2020
  No notice
• pTuneos: prioritizing tumor neoantigens from next-generation sequencing data · 2019
  Not checked
• Accuracy assessment of fusion transcript detection via read-mapping and de novo fusion transcript assembly-based methods · 2019
  No notice
• Dangerous liaisons: interplay between SWI/SNF, NuRD, and Polycomb in chromatin regulation and cancer · 2019
  No notice
• Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution · 2019
  Corrected
• The Need for Multi-Omics Biomarker Signatures in Precision Medicine · 2019
  No notice
• Cyclin A2/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress · 2018
  No notice
• Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma · 2018
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.